Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. OLMETEC (olmesartan medoxomil)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
  • Date 25 February 2004
  • Documents : 1
  • History
Listen Listen
Add to my selection
    Quote this publication
    Share
    Share on
    Facebook share - facebook.com - new window
    Tweeter share - Partager sur Twitter - twitter.com - new window
    LinkedIn share - linkedin.com - new window
    Print

    OLMETEC (olmesartan medoxomil)

    Opinions on drugs - Posted on Feb 25 2004 - Updated on Aug 14 2006

    Documents

    • Avis_médicament_ct031538.pdf Xvox

    Contact Us

    Évaluation des médicaments
    • Contact Us
    All our publications
      Drug therapy Hypertension

    Follow us :

    • Twitter (nouvelle fenêtre)
    • Facebook (nouvelle fenêtre)
    • Youtube (nouvelle fenêtre)
    • LinkedIn (nouvelle fenêtre)
    Haute Autorité de Santé
    Advancing quality in the fields of health and social care services
    • Eunetha.eu
    • Pasq.eu
    • All our publications by topic and type
    • Opinions on medicines
    • Opinions on medical devices
    • INAHTA briefs
    • Français
    • English
    eNq1mNuO2jAQhu95iij3JJyWQxVYtXRpkXZVyoJa9QaZZADTYGd94NCnr0NYFSpHuzj4Mrbzz8Tz+/Mowf1+EztbYBxT0nWrXsV1gIQ0wmTZdaeTQbnt3vdKwRpt0dmyllfxqjXXCWPEeddNZ705IMK9n0+Pn0G9D8ztlZyAztcQiot1UuDY+4r46gkl6Ron2FIcORsQKxp13USK46gTcMFUFr0dZb95gkII/NPI+ex61jgfD/xU7B2qkgN7RGSpFQVipBlKxoCIPhKwpOyglV6Es1q71axU2kYhMB8Dp5KFMEJiNWJ0iyOI9JFQzMEoyGIXPQPbxiDSIFpxfx1uuJE4WqP9GF6G+qQ/qtm+2ItypVxt3TUa7Wa93qxXW0ah2NlW6c2jPsIPZ/VOp9PsGNZjRJlAsaVKYN6/9JSlOAxe3qx4hHkSo4O35onpViGG1DQwdfLtfUj6BROmWBSrPftPn8g49q/MenoihaWMUxD1qSQiBxiDselG9CkRsM+vqBnjxP7kRQz8drJ/KNHzfSTnMQ5NMaZAI4GL6XiYT7GiAPiEOEyZPQL8wCSiO357spxX0lL2yRGOWtGERdVZrdNuVu/ujA/OL2WbnJvkQTKagK+Yg3kRlAzJghaFiHKiXurVh4UseGxlaIhiyGlmyoYMUd577b2sudveyckmtKJfHiamlvgugR2ej49aaRx1CxUztAFt5b/cvK93c3ao39HlNtr1mpmjmZ4ZKyES/sH3d7udt0K8zJHaLG/BbsLxs+vSXl9t5U7OepSMhZZSn2eX3HVVMT1jb93aRTvR0/unjlcbQzAJBWqR4dgaNIcPt+fwvzbUWtqjC3DYC3NsGZHAlNhqa+Rcq1iQQEMyYIoP3xYLnPO3I9eWgZ/9aemVAj/9y9Ir/QW/8Naz
    28Twr3rGp9tczBW5